Diabetes mellitus and prostate cancer risk

The Prostate ◽  
2008 ◽  
Vol 68 (10) ◽  
pp. 1126-1132 ◽  
Author(s):  
Brandon L. Pierce ◽  
Stephen Plymate ◽  
Elaine A. Ostrander ◽  
Janet L. Stanford
2013 ◽  
Vol 22 (6) ◽  
pp. 1102-1109 ◽  
Author(s):  
Katja Fall ◽  
Hans Garmo ◽  
Soffia Gudbjörnsdottir ◽  
Pär Stattin ◽  
Björn Zethelius

2013 ◽  
Vol 16 (2) ◽  
pp. 181-186 ◽  
Author(s):  
Y R Lawrence ◽  
O Morag ◽  
M Benderly ◽  
V Boyko ◽  
I Novikov ◽  
...  

2012 ◽  
Vol 13 (8) ◽  
pp. 4097-4100 ◽  
Author(s):  
Xiang-Ju Long ◽  
Shan Lin ◽  
Ya-Nan Sun ◽  
Zhen-Feng Zheng

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 130-130
Author(s):  
Ausvydas Patasius ◽  
Marius Kincius ◽  
Donata Linkeviciute-Ulinskiene ◽  
Lina Zabuliene ◽  
Giedre Smailyte

130 Background: An inverse association has been shown between diabetes and prostate cancer risk. The aim of this study was to determine whether type 2 diabetes mellitus (T2DM) and metformin is associated with prostate cancer risk. Methods: A retrospective cohort design was used to examine the relationship between diabetes and prostate cancer risk. The cohort was composed of male patients identified with diagnosis of T2DM in the National Health Insurance Fund database during 2000–2016. Cancer cases were identified by record linkage with the Lithuanian Cancer Registry which is a nationwide population-based cancer registry that contains personal and demographic information, as well as information on diagnosis of all people diagnosed with cancer in Lithuania since 1978. We calculated standardized incidence ratios (SIRs) for prostate cancers as a ratio of observed number of cancer case in people with diabetes diagnosis to the expected number of cancer cases in the underlying general population. Results: Overall, 68,449 males were diagnosed with diabetes in Lithuania between 2000 and 2016 were included in final cohort. 2,754 prostate cancers were observed versus 3,111.26 expected within a period of observation entailing an SIR of 0.89 (95% CI: 0.85–0.92). Significantly lower risk of prostate cancer was found in diabetic patients in all age groups, there were no differences in prostate cancer risk by time since diabetes diagnosis. Significantly lower risk of prostate cancer also was found in both metformin users and never-users groups, with higher risk reduction in metformin users (SIR 0.71, 95% CI: 0.68–0.75) than in T2DM patients never-users (SIR 0.88, 95% CI: 0.80–0.96). Conclusions: In the large population-based study we found significantly decreased risk of prostate cancer among men with T2DM. Our study suggests that metformin use in patients with T2DM may be associated with reduced risk of developing prostate cancer.


2010 ◽  
Vol 5 (6) ◽  
pp. 787-789
Author(s):  
Jeffrey K Mullins ◽  
Stacy Loeb

2019 ◽  
Vol 104 (12) ◽  
pp. 6017-6024
Author(s):  
Yi X Chan ◽  
Helman Alfonso ◽  
P Gerry Fegan ◽  
Leon Flicker ◽  
Bu B Yeap

Abstract Context Diabetes mellitus is conventionally associated with an increased risk of cancer; however, inverse associations of diabetes with prostate cancer are well described. Mechanisms are unclear, although hormonal factors, including alterations in sex hormone and IGF1 concentrations due to metabolic disturbances, have been hypothesized to play a role. Objective To assess sex hormones, IGF1, glucose, and advanced glycation end products (AGEs) as potential mediators of the association between diabetes mellitus and prostate cancer. Design and Participants Longitudinal cohort study. The association of baseline diabetes with prostate cancer incidence was assessed using proportional hazards competing risks analysis in 3149 men followed for 12 years. Baseline hormone, glucose, and carboxymethyllysine (CML) levels were examined as potential mediators of this association. Results Diabetes was associated with a lower prostate cancer risk (fully adjusted subhazard ratio, 0.63; 95% CI, 0.43 to 0.92; P = 0.017). This association was unchanged after accounting for testosterone, DHT, estradiol, or SHBG. Similarly, the addition of IGF1 or its binding proteins 1 and 3, or glucose, did not alter this association. CML was not associated with the risk of prostate cancer, and additional correction for CML in the fully adjusted model did not alter the inverse association of diabetes and prostate cancer risk. Conclusions In this study, alterations in sex hormone, IGF1, glucose, and CML levels did not account for the inverse association of diabetes and prostate cancer risk. Further studies are required to provide more insight into underlying causes of this association.


2014 ◽  
Vol 191 (4S) ◽  
Author(s):  
Young Ju Lee ◽  
Jungyo Suh ◽  
Taesik Ahn ◽  
Sung Yong Cho ◽  
Seung Bae Lee ◽  
...  

2007 ◽  
Vol 18 (5) ◽  
pp. 493-503 ◽  
Author(s):  
Brook A. Calton ◽  
Shih Chen Chang ◽  
Margaret E. Wright ◽  
Victor Kipnis ◽  
Karla Lawson ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document